Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
Mallinckrodt
Merck

Last Updated: August 11, 2022

Investigational Drug Information for Zamicastat


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Zamicastat?

Zamicastat is an investigational drug.

There have been 11 clinical trials for Zamicastat. The most recent clinical trial was a Phase 2 trial, which was initiated on June 6th 2019.

The most common disease conditions in clinical trials are Hypertension, Pulmonary Arterial Hypertension, and Familial Primary Pulmonary Hypertension. The leading clinical trial sponsors are Bial - Portela C S.A., Covance, and [disabled in preview].

There are eleven US patents protecting this investigational drug and one hundred and twenty-six international patents.

Recent Clinical Trials for Zamicastat
TitleSponsorPhase
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAHBial - Portela C S.A.Phase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058Bial - Portela C S.A.Phase 1
Effect of BIA 5 1058 on Cardiac RepolarizationCovancePhase 1

See all Zamicastat clinical trials

Clinical Trial Summary for Zamicastat

Top disease conditions for Zamicastat
Top clinical trial sponsors for Zamicastat

See all Zamicastat clinical trials

US Patents for Zamicastat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Zamicastat See Plans and Pricing Process for preparing 1,3-dihydroimidazole-2-thione derivatives Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT) See Plans and Pricing
Zamicastat See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Zamicastat See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
Zamicastat See Plans and Pricing 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT) See Plans and Pricing
Zamicastat See Plans and Pricing Processes for preparing medicaments for the treatment of cardiovascular diseases and intermediates for use therein Bial-Portela & CA, S.A. (S. Mamede do Coronado, PT) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Zamicastat

Drugname Country Document Number Estimated Expiration Related US Patent
Zamicastat European Patent Office EP2726454 2031-06-29 See Plans and Pricing
Zamicastat Spain ES2667099 2031-06-29 See Plans and Pricing
Zamicastat Japan JP2014520796 2031-06-29 See Plans and Pricing
Zamicastat Japan JP5981539 2031-06-29 See Plans and Pricing
Zamicastat Portugal PT2726454 2031-06-29 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.